Skip to main content

Business Wire India


Clinical courses


Clinical research courses

  • Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic T Cell Therapies Addressing Solid Tumors

    Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.

  • Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function

    Vifor Pharma andAngion Biomedica Corp announced that the phase-III trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing DGF.

  • Experts Discuss Gender and Stigma Barriers to TB Care at Union Conference

    Global Coalition Against Tuberculosis (GCAT) and Karnataka Health Promotion Trust (KHPT) jointly organized the session The policymaker’s roundtable: Addressing gender and stigma barriers to TB Care on 21st October 2021 at the 52nd Union Conference held virtually. The panel members discussed the role of gender and stigma affecting access to TB services and care and the need for a TB-Mukt Bharat.

  • Merck Announces Mutual Decision to End Bintrafusp Alfa Agreement With GSK

    Merck, a leading science and technology company, today announced a mutual decision with GSK to terminate their agreement on bintrafusp alfa, effective September 30, 2021.

    The decision is based on the clinical trial data generated to date, most notably the previously reported results from the INTR@PID Lung 037 study, which did not replicate the encouraging data observed in earlier studies. Based on the data generated during the agreement, no milestone payments were made by GSK and no future milestone obligations remain.

  • Galderma to Present New Data From Leading Aesthetics Portfolio and Launch RESTYLANE EYELIGHT at AMWC 2021

    Galderma announced new results from its robust pipeline and portfolio of dermal fillers and toxin injections. Eleven e-posters from Galderma-sponsored and investigator-initiated trials have been accepted at the upcoming Aesthetic & Anti-Aging Medicine World Congress (AMWC), taking place in Monaco and virtually on September 16–18, 2021.

  • Medtronic Launches Percept PC - the First and Only DBS System With BrainSense Technology

    India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc announced the launch of the Percept PC Deep Brain Stimulation system. The system enabled with BrainSense technology is designed to capture brain signals while simultaneously delivering therapeutic stimulation, inside and outside the clinic. Ergonomically designed, the Percept PC device offers enhanced comfort and is indicated for patients with Parkinson’s disease, tremor, dystonia, and epilepsy.

  • Regdanvimab demonstrates strong neutralising activity against Delta variant of COVID-19

    Celltrion Group today announced new results from an in vivo efficacy study showing that regdanvimab, CT-P59 has a strong neutralising effect against the rapidly spreading Delta variant, B.1.617.2, first identified in India.

    According to the World Health Organization, WHO, the Delta variant has been reported in 96 countries becoming the most common variant.1

  • Curia to Acquire US-Based LakePharma

    Established in 2009 in the Bay Area, LakePharma applies its range of technology platforms to advance projects from discovery to development to manufacturing, namely cell-line development, bioexpression systems and viral vector production systems. Almost a quarter of its employees hold Ph.D.s, bringing expertise in all major biologics segments: mammalian, microbial, plasmid DNA, mRNA, monoclonal antibodies, and viral vector, including cell and gene therapy.

  • Aragen Announces Expansion of Discovery Research Agreement with Boehringer Ingelheim

    Aragen Life Sciences (formerly GVK BIO), a leading Contract Research and Development Organization, headquartered out of Hyderabad, India, announces an expansion of their discovery research agreement with Boehringer Ingelheim, with the goal of accelerating the discovery pipeline of Boehringer Ingelheim.

  • Grand Prize Winner Announced in USD 5M IBM Watson AI XPRIZE Competition

    XPRIZE, the worlds leader in designing and operating incentive competitions to solve humanitys grand challenges, and IBM Watson, IBMs AI technology for business, today announced the Grand Prize Winner in the USd 5M IBM Watson AI XPRIZE Challenge. First launched in 2016, the five-year global competition looked to accelerate adoption of artificial intelligence (AI) technologies and spark creative, innovative and audacious demonstrations of the technology that are truly scalable to solve societal grand challenges.

Subscribe to Business Wire India